دورية أكاديمية
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial
| العنوان: | High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial |
|---|---|
| المؤلفون: | Kalogeropoulos, Andreas P., Tang, W. H. Wilson, Hsu, Amy, Felker, G. Michael, Hernandez, Adrian F., Troughton, Richard W., Voors, Adriaan A., Anker, Stefan D., Metra, Marco, McMurray, John J.V., Massie, Barry M., Ezekowitz, Justin A., Califf, Robert M., O’Connor, Christopher M., Starling, Randall C., Butler, Javed |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2014 |
| المجموعة: | University of Glasgow: Enlighten - Publications |
| الوصف: | Background Inflammation is associated with progression of chronic heart failure (HF). Few data exist on high-sensitivity C-reactive protein (hsCRP) levels and their importance in acute HF. Methods and Results In this biomarker substudy of the ASCEND-HF trial, we measured hsCRP levels at admission (n = 794), 48–72 hours (n = 677), and 30 days (n = 581) and evaluated their association with outcomes. Levels of hsCRP were considerably elevated at admission (median 12.6 mg/L, interquartile range [IQR] 5.23–30.5) and 48–72 hours (median 11.0 mg/L, IQR 4.87–29.9) and declined only at 30 days (median 4.7 mg/L, IQR 1.83–13.1). Admission hsCRP was not associated with dyspnea improvement at 6 hours (74.1%) and 24 hours (86.2%), in-hospital death or worsening HF (n = 37; 4.7%), 30-day mortality or HF readmission (death: n = 25 [3.2%]; combined death and HF readmission: n = 95 [12.0%]), or 180-day mortality (n = 96; 12.1%). Hospital stay (median 5 days, IQR 3–7) was longer among patients with higher admission hsCRP levels (0.57 days per log2-hsCRP in adjusted models; 95% confidence interval [CI] 0.33–0.81; P < .001). Levels of hsCRP at 48–72 hours did not predict 30-day mortality or HF readmission and were only marginally associated with 180-day mortality. However, higher hsCRP at 30 days among survivors was associated with higher 180-day mortality in models including admission hsCRP (adjusted hazard ratio [HR] per log2-hsCRP: 1.23; 95% CI 1.04–1.45; P = .016). Patients with an hsCRP increase at day 30, defined as >10% increase over baseline value, had higher 180-day mortality risk compared with those with unchanged or decreased 30-day hsCRP (HR 2.29, 95% CI 1.16–4.52; P = .017). Conclusions Levels of hsCRP are elevated among patients with acute HF. Increasing levels at 30 days after discharge are associated with higher 180-day mortality. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Kalogeropoulos, A. P. et al. (2014) High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure , 20(5), pp. 319-326. (doi:10.1016/j.cardfail.2014.02.002 ) (PMID:24530944) |
| الإتاحة: | https://doi.org/10.1016/j.cardfail.2014.02.002Test http://eprints.gla.ac.uk/94251Test/ |
| رقم الانضمام: | edsbas.2E2D6BB |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |